A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

NCT02510300 · clinicaltrials.gov ↗

TERMINATED

Status

461

Enrollment

INDUSTRY

Sponsor class

Stopped The study stopped early because the study objectives were met.

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: Sofosbuvir (SOF)
DRUG: Ledipasvir/Sofosbuvir (LDV/SOF)
DRUG: Sofosbuvir/Velpatasvir (SOF/VEL)
DRUG: Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)

Sponsor

Gilead Sciences